Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Praxis Precision Medicines ( (PRAX) ) is now available.
On December 9, 2025, Praxis Precision Medicines announced the completion of a Type C meeting with the FDA, resulting in the conversion of the EMBRAVE3 study of elsunersen into a single-arm study for early-onset SCN2A developmental and epileptic encephalopathy. This change involves enrolling 30 patients, all of whom will receive elsunersen, with the primary analysis focusing on motor seizure changes. Additionally, on December 11, 2025, the company confirmed plans to file a New Drug Application for relutrigine in early 2026, following discussions with the FDA.
The most recent analyst rating on (PRAX) stock is a Buy with a $420.00 price target. To see the full list of analyst forecasts on Praxis Precision Medicines stock, see the PRAX Stock Forecast page.
Spark’s Take on PRAX Stock
According to Spark, TipRanks’ AI Analyst, PRAX is a Neutral.
Praxis Precision Medicines’ overall stock score is driven by significant financial challenges, despite strong technical momentum and positive corporate developments. The financial performance is a major concern, but recent study successes and regulatory progress provide potential for future growth.
To see Spark’s full report on PRAX stock, click here.
More about Praxis Precision Medicines
Praxis Precision Medicines operates in the pharmaceutical industry, focusing on developing treatments for neurological disorders. The company is engaged in creating therapies for conditions such as developmental and epileptic encephalopathy.
Average Trading Volume: 1,028,933
Technical Sentiment Signal: Buy
Current Market Cap: $6.46B
See more insights into PRAX stock on TipRanks’ Stock Analysis page.